Mitochondrial Function After Ketamine

Assessment of Mitochondrial Parameters in Blood Before and After S-Ketamine Treatment

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07399756

Enrollment

Registered

2026-02-10

Start date

2026-02-01

Completion date

2028-01-01

Last updated

2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

ketamine, Mitochondrial, Treatment-Resistant Depression

Brief summary

The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1. Does S-ketamine treatment modulate mitochondrial function in peripheral blood cells, as reflected by mitochondrial content and circulating mitochondrial biomarkers such as GDF15? 2. Can changes in mitochondrial function serve as biomarkers for predicting or monitoring clinical response to S-ketamine treatment? Samples will be collected at baseline, 3 hours after the first treatment, and 6 weeks post-exposure, and compared between responders and non-responders

Interventions

DRUGS (+) Ketamine

the patients are treated with S-Ketamine in order to treat there Treatment-Resistant Depression via inhalation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Male or female, 18-65 years of age Diagnosis of Major Depressive Disorder according to the DSM-V Patient has a HAM-D≥23 Treatment resistant -Did not respond to two antidepressants trial Medically stable: No active physical disease: malignancy, cardiac condition, hypertension , stable medications for the past month etc.

Exclusion criteria

Known sensitivity to ketamine drug or alcohol abuse Patient taking lithium or corticosteroids Pregnant or breast-feeding has another axis I diagnosis attention deficits disorder a history or current serious neurological, metabolic autoimmune bone marrow, oncologic or additional psychiatric disorders

Design outcomes

Primary

Measure	Time frame	Description
S-ketamine effects on the mitochondrial	3 hours and 6 weeks	Does S-ketamine treatment modulate mitochondrial function in peripheral blood cells, as reflected by mitochondrial content and circulating mitochondrial biomarkers such as GDF15?

Countries

Israel

Contacts

CONTACTrevital amiaz, dr

revital.amiaz@sheba.health.gov.il972 035302538

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026